---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-121069"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2024-11-05T23:59:59+00:00"
generated_at: "2026-05-30T05:25:23.149228+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Beam Therapeutics Q3 net loss $96.7M; cash $925.8M; BEAM-101 enrollment at 35 patients

## Summary
- Net loss $96.7M ($1.17/share) vs $96.1M ($1.22) Q3 2023; R&D $94.3M, G&A $26.5M.
- Cash, equivalents, and marketable securities $925.8M as of Sep 30, 2024; runway into 2027.
- BEACON trial of BEAM-101: 35 patients enrolled, 8 dosed in sickle cell disease; ASH data Dec 2024.
- First cohort dosing complete for BEAM-302 in alpha-1 antitrypsin deficiency; initial data expected 2025.
- ESCAPE platform (BEAM-103/104) nominated for development in SCD and beta-thalassemia.

## SEC filing metadata
- accession: 0000950170-24-121069
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2024-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000095017024121069/0000950170-24-121069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000095017024121069/beam-20241105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-121069
- JSON: https://secwatch.observer/filing/0000950170-24-121069.json
- Plain text: https://secwatch.observer/filing/0000950170-24-121069.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.